Format

Send to

Choose Destination
Dermatology. 2008;216(2):133-6. doi: 10.1159/000111510. Epub 2008 Jan 23.

Pimecrolimus 1% cream in the treatment of facial psoriasis: a 16-week open-label study.

Author information

1
Department of Dermatology, University Hospital Marburg, Marburg, Germany. Arnd.Jacobi@med.uni-marburg.de

Abstract

BACKGROUND:

Facial psoriasis requires a treatment approach other than topical corticosteroids which bear the risk of skin atrophy. Topical pimecrolimus has been shown to be effective in atopic eczema and recently in psoriasis.

OBJECTIVE:

The aim of this open-label single-center investigator-initiated study was to evaluate the efficacy and safety of pimecrolimus 1% cream in patients with facial psoriasis.

METHODS:

20 adults with facial psoriasis were enrolled. Pimecrolimus 1% cream was applied twice daily to psoriatic lesions of the face over an 8-week period. An 8-week follow-up was added.

RESULTS:

All clinical parameters showed a significant improvement after 8 and 16 weeks compared to baseline. Pimecrolimus 1% cream was effective and well tolerated.

CONCLUSIONS:

This is the first clinical study with a larger patient cohort reporting a relevant therapeutic effect and favorable safety profile of pimecrolimus 1% cream in facial psoriasis.

PMID:
18216475
DOI:
10.1159/000111510
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center